Impact News +++ Magnum Ice Cream Co serves up mixed first final results after demerger (Proactive Investors) +++ MAGNUM ICE CREAM Aktie -9,62%

VIKING THERAPEUTICS Aktie

>Aktienkurs

26.9 EUR +11.7% (TradegateBSX)

Ask: 26.9 EUR / 3000 Stück

Bid: 26.5 EUR / 3000 Stück

Tagesumsatz: 17155 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: -3,4%

1 Monat: -12,5%

3 Monate: -31,3%

6 Monate: -26,5%

1 Jahr: -15,4%

laufendes Jahr: -22,7%

>VIKING THERAPEUTICS Aktie

Name:

VIKING THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US92686J1060 / A12GD6

Symbol/ Ticker:

1VT (Frankfurt) / VKTX (NASDAQ)

Kürzel:

FRA:1VT, ETR:1VT, 1VT:GR, NASDAQ:VKTX

Index:

Webseite:

https://www.vikingtherape..

Profil:

Viking Therapeutics Inc. is a biopharmaceutical co..
>Volltext..

Marktkapitalisierung:

2783.29 Mio. EUR

Unternehmenswert:

2174.26 Mio. EUR

Umsatz:

EBITDA:

-230.59 Mio. EUR

Nettogewinn:

-199.5 Mio. EUR

Gewinn je Aktie:

-1.78 EUR

Schulden:

0.63 Mio. EUR

Liquide Mittel:

84.35 Mio. EUR

Operativer Cashflow:

-188.73 Mio. EUR

Bargeldquote:

27.41

Umsatzwachstum:

Gewinnwachstum:

-127.18%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

VIKING THERAPEUTICS, VIKING THERAPEUTIC

Letzte Datenerhebung:

12.02.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 113.04 Mio. St.

Frei handelbar: 97.05%

Leerverk. Aktien: 23.06%

Rückkaufquote: -0.07%

Mitarbeiter: 36

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 247.32%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 4.26

PEG-Ratio: -0.1

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -28.31%

Eigenkaprendite: -29.23%

>Peer Group

Gesundheit

>Chart & Kurs - NASDAQ

>Alle News

12.02.26 - 06:51	Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 06:48	Viking Therapeutics bringt Abnehmpille in finale Studie - Aktie steigt (Cash)
	Pharma - Bei seiner Gewichtsverlust-Pille erreicht Viking Therapeutics die letzte Studienphase....

11.02.26 - 23:49	Viking Therapeutics verfehlt EPS-Prognose für Q4 2025 deutlich (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.26 - 22:18	Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update (PR Newswire)
	Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment VK2735 Maintenance Dosing Study Fully Enrolled;......

11.02.26 - 07:48	Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can′t Ignore (Fool)
	This stock has been known to soar after good news....

04.02.26 - 22:09	Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 (PR Newswire)
	Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine......

31.01.26 - 01:00	Here′s Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market (Zacks)
	Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $29.06, signifying a -3.9% move from its prior day's close....

26.01.26 - 17:36	Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? (Fool)
	Both companies may succeed in this industry....

24.01.26 - 01:00	Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts (Zacks)
	Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.22, moving 5.49% from the previous trading session....

20.01.26 - 21:36	What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? (Fool)
	Despite a challenging year, the company has a lot to look forward to in the coming years....

16.01.26 - 01:00	Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
	Viking Therapeutics, Inc. (VKTX) reached $31.86 at the closing of the latest trading day, reflecting a -7.21% change compared to its last close....

12.01.26 - 13:03	Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity (PR Newswire)
	Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in Obesity SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)......

11.01.26 - 12:48	What Investors Should Know About a Viking Therapeutics Insider′s $2 Million Stock Sale (Fool)
	This clinical-stage biotech developing metabolic therapies reported a notable insider sale amid a challenging year for its stock....

10.01.26 - 01:00	Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know (Zacks)
	Viking Therapeutics, Inc. (VKTX) reached $31.99 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close....

09.01.26 - 17:30	VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug (Zacks)
	Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults....

08.01.26 - 16:45	Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet (Zacks)
	Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...

08.01.26 - 13:03	Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity (PR Newswire)
	Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage......

07.01.26 - 13:03	Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer (PR Newswire)
	Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies......

07.01.26 - 01:09	Here′s How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today (Benzinga)
	read more...

06.01.26 - 08:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Viking Therapeutics im Wert von 1896969 USD (Insiderkauf)
	Zante, Greg - Vorstand - Tag der Transaktion: 2026-01-05...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Mag alles Leid und Schatten sein - doch diese süße Sonnenstunde nicht, und nicht der Duft vom roten Klee, und nicht das tiefe, zarte Wohlgefühl in meiner Seele. - Hermann Hesse

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram